


WELBLU- Emerging Antiviral Product

Dengue Project.



INSIGHT

- Dengue & Welblu Solution

Challenges & Opportunity

- Anti- infective Healthcare


Emerging Technology : our job

- Strategy Plan & Execution

Business model and roadmap

- An expert Management

Team and Mission



400 million Dengue infected & 100 million symptomatic cases annually

141 countries affected by the most rapidly resulting 36,000 fatalities

30-fold increase in global incidence over the past 50 years – No treatment available till date

CAGR of 25.5% - Forecast Period of 2021 to 2028



- Wrist **wearable medical device** - emits low level light therapy
- Sub-lingual drug consisting of repurposed drug




- Drug - **1ml sublingual** administered **once a day** + low level light therapy wristband placed on the wrist
- Activated for **10 minutes** with Low Level Light Therapy before being placed sublingually and After Dosing for 50 min
- **Repeat cycle:** 60min Light therapy x 1ml drug x 7 - 10 days.

Product -USP




- All Active and Excipient levels as per **GRAS & FDA IIG limits**
- No risk of developing **resistance** against variant systemic
- **Sublingual delivery** for faster absorption and quick action
- Ease of Administration – **Self/ Twice -a-day** consumption
- Rechargeable wrist band
- Safety -**128 Years** of Drug Existence

Photo Dynamic Therapy




The propoagation of light of different wavelengths in the tissues.




WELBLU dual action Disintegrate double envelope virus and activate Immune cascade pathway


An innovative and multi-target approach, enabled by a specific expertise of repurposed drug & devices synergy




A high level of evidence, with clinical studies and health claims



A pipeline of innovative anti-infective healthcare solution, developed in our R&D centers



Patent filed & regulatory interaction in 3 continents



Clinical Study Control

- **Monitoring:** Daily clinical improvement were evaluated for seven days of patient temperature , arterial oxygen saturation and other vital signs measurement.
- **Laboratory & Cabinets test :**First day of admission and on seventh day, blood samples were drawn to assess chemistry as per table

| Immune Marker | Inflammation Marker | Haematological Studies | Radiological |
|---------------|-----------------------------|---|---------------|
| G6PD | C- Reactive Protein | Complete Hematic Biometrics & Blood Chemistry | Chest – X ray |
| IgG | Globular Sedimentation Rate | Including Liver & Kidney Panel | NA |
| IgM | Pro – calcitonin | Pulse Oximetry | NA |
| NA | Ferritin Levels & IL -6 | D - dimer | NA |

- Daily **PCR Swabs** measuring cycle threshold (CT) were collected (period: 1 – 7 days)
- **Outcome:** This study has shown that COVID positive patients who have undergone treatment using **Welblu** became COVID negative, after receiving just one to three daily doses. Patients that were positive for Covid-19 but not treated with **Welblu** showed an average of 3 weeks before achieving negative test results using regular treatment line.

Technology Action Line



Immunity & Wellbeing



Immunomodulatory, Anti-inflammatory, Pan-fungicidal & Pan-bactericidal

Control



Alkalizing- Virucidal, Anti-coagulant, Prevent septic shock, Cytokine Storm

Rejuvenation Support














Oxygen superoxide scavengers, Increased oxygen saturation

Lifestyle Wellness Support




Anti depressant (serotonin analogue)

Road Map

| Key Tasks | 2019 -22 | | | 2023 | | | | 2024/25 | | | |
|---|--|--|---|---|---|---|---|---|----|---|---|
| | Q 1 & 2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 & Q1 |
| Technology Development & POC |  | | | | | | | | | | |
| | | |  | | | | | | | | |
| Set up – Scale Up and Clinical Manufacturing |  | | | | | | | | | | |
| Clinical Studies | | | | |  | | | | | | |
| Small scale, GCP, GMP compliant Manufacturing | | | |  | | | | | | | |
| Marketing Authorization | |  | | | |  |  | | | | |
| Planning and Launch (partner) | | | | | | | |  | | | |
| Ongoing Commercial Grade Production | | | | | | | | | |  |  |

REGULATORY PATHWAY

De novo drug discovery



Business Strategy

Long term strategic partnerships



A double model, to generate growth:

1. License agreements:

Lump sum payments: upfront,
milestones

+ Royalties on sales



2. Supply agreements

Commercialization model



Target population

Subjects at risk of
developing metabolic
diseases



Advisors


Healthcare professionals




Govt & NGO

Pharmacies / drugstores strategy by countries Impacted


GLOBAL ANTIVIRAL DRUG MARKETS



VIRAL OUTBREAK TRENDS



OUR TECHNICAL EXPERTS



Dr. Rajendra Bhandari
Chairman - Focelite



Vijay Kumar Ranka
Managing Director



Dr. Praveen S Sancheti
Clinical advisor



Dr. Jagdeep Kakadia
Medical Advisor

Our Supervisory Board

- Anant Pandya - Regulatory & Pharmaceutical expert
- Dr. Jitendra Kumar- Managing Director of Bangalore Bio-innovation Centre
- Dr.Vinayaka Srinivas - Scientific expert
- Dr. A.Rajini - Regulatory Advisory
- Dr Deepak Golwalkar - Pulmonologist & Methylene Blue Clinical Advisor
- Soudagar GH - Quality & Manufacturing
- Komal Minhas - Project Management

Our Advisory Board

- Mr.Rishav Saraf - Financial Advisor
- Mr.Manish S.Shah - Program Partner
- Mr.Prashanth Priya - Public Relation Advisor
- Mr.Anand Bhogu - Business Advisor
- Mr. Abhijit - Legal Advisor
- Mr.Sripal Jain - Board Advisor
- Mrs.Renu kaul - Scientific Writer
- Dr.Meena Shah - Emergency Filing regulatory Advisor
- Yogesh - Medical Devices Regulatory Advisor
- Paras Jain - Clinical Program Monitoring & Audit
- Parithosh K. Tungaturthi - Patent Advisor



Our Mission

New cases of microbial infection and viral emergency , including antimicrobial resistance, Dengue are on the rise which pose the greatest public health risk due to their epidemic potential along with a need for countermeasures.

At Focelite, Our Research & Development revolves around anti-infective healthcare products. Repurposing of Drugs and use in synergy with a non- invasive low wavelength light emitting device has been proven beneficial due to its multi-target activity and dual action.

Our goal - Reduce the impact these diseases may have on millions of at-risk individuals, worldwide.

Focelite is a player committed to treatment tending towards the upliftment of public health

Thank You

 **Vijay Kumar Ranka**


 **+91 9591974355**

 **vijay@focelite.com**


 **www.welblu.com : www.focelite.com**

© 2021, Focelite Goodness India Pvt. Ltd. All Rights Reserved.

Symptoms of Dengue Fever



895403602



Evolution of Antiviral Drug Discovery

